Welcome to the 4th Circular & Self-Amplifying RNA Therapeutics Summit
Unleashing the Next Generation of RNAs for Widespread Therapeutic Applications
The 4th Circular & Self-Amplifying RNA Therapeutics Summit (formerly known as '3rd Next Generation RNA Therapeutics Summit) is returning to Boston this May to unite leading stakeholders within the next generation RNA field, including the likes of Sail Biomedicines, Merck, Novo Nordisk, Replicate Bioscience and more.
This is the only industry dedicated event showcasing the latest approaches and applications of these next generation RNAs for more potent and durable treatment of a wide array of diseases to help your company gain actionable insights for fast-tracking your RNA programs towards the clinic.
Join 80+ RNA experts navigating through challenges such as RNA design, delivery, purity, and manufacturing to accelerate high-quality and scalable next generation RNA therapeutics and vaccines towards approval and the patients in need.
What's New for 2025?
1.Brand New Speaker Faculty & Exclusive Data
With over 80% new speakers from key stakeholders, hear brand-new data and insights from the likes of CSL Seqirus, Merck & Co, Sail Biomedicines, RiboX Therapeutics, VLP Therapeutics and more, gain insights into promise of circular and self-amplifying RNA for providing more durable, stable and potent therapeutics and vaccines.
2. Addressing Circular & Self-Amplifying RNA Bottlenecks
As an event-dedicated to the next generation RNA community, we're excited to provide you with deep dive workshops, data-driven presentations and interactive discussion addressing challenges in manufacturing, purification, optimal application, analysis and more to help you advance RNA therapies towards approval.
3. Improving Next Generation RNA Investment
During an interactive fireside chat with MPM Capital and Orbital Therapeutics, hear what innovations are needed to spark greater investment in the circular and self-amplifying RNA field. This session will highlight priority actions and applications for driving more success in the next generation RNA field.